The IQGAP1 Knockout A-549 Polyclonal Cells product comprises a population of A-549 cells subjected to CRISPR/Cas9-mediated disruption of the IQGAP1 gene, generating a polyclonal knockout pool. This format provides a genetically heterogeneous collection of loss-of-function mutants suitable for studying the collective impact of IQGAP1 ablation in a lung carcinoma background. As a polyclonal population, these cells mirror the natural genetic variation that arises during CRISPR editing, enabling robust functional assays without the clonal selection biases associated with isolated single-cell clones.
The A-549 host cell line is a widely studied adherent human lung carcinoma epithelial line originally derived from a 58-year-old Caucasian male. Serving as a model for type II alveolar epithelial cells, A-549 cells are employed in investigations of lung adenocarcinoma, respiratory biology, and drug metabolism. The cell line??s well-characterized signaling pathways and epithelial morphology make it a relevant platform for examining oncogenic mechanisms and therapeutic responses in non-small cell lung carcinoma.
IQGAP1 is a multi-domain scaffold protein that orchestrates cytoskeletal dynamics and cell adhesion by integrating signals from growth factor receptors and Rho family GTPases. It directly interacts with calmodulin, actin, E-cadherin, ??-catenin, CDC42, and RAC1, and functions upstream of the MEK?CERK phosphorylation cascade and mTOR pathway. In response to upstream activators such as EGF, HGF, EGFR, or MET, IQGAP1 coordinates actin polymerization and cadherin-mediated adhesion, thereby regulating cell migration and proliferation. The scaffold also associates with CLIP-170 and APC, linking microtubule dynamics to cortical actin structures. Disruption of IQGAP1 uncouples these effector mechanisms, impairing directed migration, adhesion turnover, and invasive capacity.
The A-549 lung adenocarcinoma model provides a clinically relevant background for investigating IQGAP1-dependent processes. Because IQGAP1 is overexpressed in multiple carcinomas and correlates with poor prognosis, its knockout in A-549 cells permits systematic evaluation of phenotypic changes in migration and adhesion. This cell model is particularly suited for studying the intersection of growth factor signaling and cytoskeletal reorganization, offering a platform to identify therapeutic targets that might limit cancer cell dissemination.
Researchers can employ this polyclonal knockout population in diverse functional assays, including wound healing and Transwell migration/invasion to quantify cell motility, immunofluorescence staining to visualize actin cytoskeleton and focal adhesion architecture, and co-immunoprecipitation to validate disrupted IQGAP1 interactions such as those with E-cadherin or ??-catenin. The cells are also amenable to western blotting for phospho-ERK to assess MAPK pathway alterations and RT-qPCR for epithelial-mesenchymal transition markers. These applications support screening of anti-metastatic compounds, mechanistic dissection of scaffold protein networks, and generation of lung adenocarcinoma progression models. For further technical details, please contact Ascent Research.
